GlassScriptPhysician profile
Michael M Kwarcinski
NPI 1710975917
$2,670.74
in general payments reported to CMS, 2019-2025
14 companies · $651 in 2025
The $651 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $164 · 2021: $211 · 2022: $481 · 2023: $510 · 2024: $316 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $753.51 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $542.02 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $398.18 | 2019-2021 | |
| Alcon Vision LLC | $287.44 | 2019-2025 | Tryptyr, Precision 1, Total30 |
| Johnson & Johnson Vision Care, INC. | $199.08 | 2021-2024 | Acuvue |
| Sight Sciences, INC. | $167.17 | 2022-2024 | Tearcare System |
| Rxsight INC | $113.06 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Oyster Point Pharma, INC. | $48.21 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $43.19 | 2025 | Vevye |
| Biotissue Holdings INC. | $32.00 | 2024-2025 | |
| Dompe US, INC. | $29.23 | 2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $22.43 | 2025 | Xdemvy |
| Allergan, INC. | $17.95 | 2022 | |
| Shire North American Group INC | $17.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kwarcinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.